MedTrace Logo

The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor

NCT06311968 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2025-06-13

No results posted yet for this study

Summary

To observe the efficacy and toxicities of post-operative (R0/R1) proton radiotherapy for locally advanced primary thymus epithelial malignancies. The primary endpoint was progression-free survival and toxicities, and the secondary endpoint was overall survival and cause-specific survival.

Conditions

  • Thymus Epithelial Tumor
  • Proton Radiotherapy
  • Radiation Toxicity

Interventions

RADIATION

Proton radiotherapy

Patients who received R0 resection will receive 45GyE per 18 fractions proton irradiation. Patients who received R1 resection will receive 50GyE per 20 fractions proton irradiation. Patients with thymus cancer should receive combined platinum based chemotherapy (including etoposide combined with cisplatin / carboplatin / loplatin / nedaplatin, paclitaxel combined with cisplatin / carboplatin / loplatin / nedaplatin, Docetaxel combined with cisplatin / carboplatin / loplatin / nedaplatin) for at least 4 cycles.

OTHER

combined platinum based chemotherapy

combined platinum based chemotherapy

Sponsors & Collaborators

  • Jian Chen

    lead OTHER

Principal Investigators

  • Jingfang Mao, PHD · Shanghai Proton and Heavy Ion Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-06
Primary Completion
2027-02-28
Completion
2027-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06311968 on ClinicalTrials.gov